ADMA Biologics (ADMA) Received its Third Buy in a Row

After Oppenheimer and Maxim Group gave ADMA Biologics (NASDAQ: ADMA) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on ADMA Biologics today and set a price target of $13. The company’s shares closed on Friday at $4.93.

According to, Selvaraju is a 3-star analyst with an average return of 0.9% and a 38.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $12.70, which is a 157.6% upside from current levels. In a report issued on April 2, Oppenheimer also reiterated a Buy rating on the stock with a $16 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.96 and a one-year low of $2.08. Currently, ADMA Biologics has an average volume of 1.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.